TW445136B - Anti-stress agent and functional food having anti-stress effect - Google Patents
Anti-stress agent and functional food having anti-stress effect Download PDFInfo
- Publication number
- TW445136B TW445136B TW086111250A TW86111250A TW445136B TW 445136 B TW445136 B TW 445136B TW 086111250 A TW086111250 A TW 086111250A TW 86111250 A TW86111250 A TW 86111250A TW 445136 B TW445136 B TW 445136B
- Authority
- TW
- Taiwan
- Prior art keywords
- functional food
- agent
- lactic acid
- compression
- fermented
- Prior art date
Links
- 235000013376 functional food Nutrition 0.000 title claims abstract description 21
- 230000000694 effects Effects 0.000 title claims abstract description 18
- 230000002180 anti-stress Effects 0.000 title abstract 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 56
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 52
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 28
- 239000004310 lactic acid Substances 0.000 claims abstract description 27
- 241000894006 Bacteria Species 0.000 claims abstract description 24
- 238000007906 compression Methods 0.000 claims description 55
- 235000013618 yogurt Nutrition 0.000 claims description 29
- 235000013305 food Nutrition 0.000 claims description 11
- 238000011049 filling Methods 0.000 claims description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 7
- 235000011194 food seasoning agent Nutrition 0.000 claims description 5
- 235000013351 cheese Nutrition 0.000 claims description 4
- 239000003086 colorant Substances 0.000 claims description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 239000011707 mineral Substances 0.000 claims description 4
- 235000010755 mineral Nutrition 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 240000002605 Lactobacillus helveticus Species 0.000 claims description 3
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- 229940054346 lactobacillus helveticus Drugs 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 229940041514 candida albicans extract Drugs 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 235000020185 raw untreated milk Nutrition 0.000 claims description 2
- 150000008163 sugars Chemical class 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 239000012138 yeast extract Substances 0.000 claims description 2
- 239000004278 EU approved seasoning Substances 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- 230000003340 mental effect Effects 0.000 abstract description 17
- 239000008267 milk Substances 0.000 abstract description 15
- 210000004080 milk Anatomy 0.000 abstract description 15
- 235000013336 milk Nutrition 0.000 abstract description 14
- 208000024891 symptom Diseases 0.000 abstract description 9
- 241000186660 Lactobacillus Species 0.000 abstract description 7
- 229940039696 lactobacillus Drugs 0.000 abstract description 7
- 235000020244 animal milk Nutrition 0.000 abstract description 4
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 239000002253 acid Substances 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 32
- 239000000243 solution Substances 0.000 description 12
- 230000035487 diastolic blood pressure Effects 0.000 description 10
- 230000036772 blood pressure Effects 0.000 description 8
- 238000004364 calculation method Methods 0.000 description 8
- 239000011550 stock solution Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 6
- 230000002079 cooperative effect Effects 0.000 description 5
- 235000015140 cultured milk Nutrition 0.000 description 5
- 230000002354 daily effect Effects 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108010011485 Aspartame Proteins 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- 235000013958 Lactobacillus casei Nutrition 0.000 description 2
- 241000186840 Lactobacillus fermentum Species 0.000 description 2
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 2
- 229940017800 lactobacillus casei Drugs 0.000 description 2
- 229940012969 lactobacillus fermentum Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000006996 mental state Effects 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000021262 sour milk Nutrition 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241001000287 Helvetia Species 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 1
- DATAGRPVKZEWHA-UHFFFAOYSA-N L-gamma-glutamyl-n-ethylamine Natural products CCNC(=O)CCC(N)C(O)=O DATAGRPVKZEWHA-UHFFFAOYSA-N 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 235000003228 Lactuca sativa Nutrition 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 244000253911 Saccharomyces fragilis Species 0.000 description 1
- 235000018368 Saccharomyces fragilis Nutrition 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000015155 buttermilk Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000013409 condiments Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- -1 helium lactic acid Chemical compound 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 235000020252 horse milk Nutrition 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940031154 kluyveromyces marxianus Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000020254 sheep milk Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/137—Thickening substances
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/147—Helveticus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Dairy Products (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
445136 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明說明(1 ) 技藝領域 本發明有關具有避免且緩和壓迫所致之精神與身體症 狀功效之抗壓迫劑,以及包含該抗壓迫劑之機能性食品, 其係將抗壓迫劑添加於酸酪乳、含乳酸化飮料、乾酪、各 種加工食品、健康食品或粒化食品中製得,使其具有.抗壓 迫功效。 . 背景技藝 在現代社會中,人類遭遇高度先進且複雜之科技或劇 烈的社會環境變遷所致之各種壓力。特別是,在國際化社 會中形成複雜的人際關係,造成精神壓力。已有報告指出 有許多症狀係由精神壓力造成。 已知精神壓力對於血液循環系統有極大的影響。然而 目前壓力之科學槪念與定義尙未確立,此意謂著壓力的評 估仍有許多問題以及方法上之困難。不過,近幾年中,已 從醫療觀點硏究壓力。 例如,報告指出當人遭遇壓力時,血管緊縮素II及 /或血管加壓素增加,而且因鈉再吸收性之故,體內的鈉 過量,其導致血壓上升(Osamn Mobara等著;Taisha, 28, 2,323,1991)。然而,遭遇壓力不僅造成血壓 升高,其亦影響許多因素,因此其被認爲造成胃潰瘍、絕 血性心臟病、腦血管疾病、高血壓、高血脂等。因此,雖 然診査壓力與高血壓之間的關係極重要,一般不認爲僅降 低血壓可帶來抗壓迫功效。 本紙張尺度適用中國國家標準(CNS)A4規格(2】0 X 297公釐) -----Γ4ιι_---裝----------訂 ---------線 >- (請先W讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 ^ 445136 A/ B7 五、發明說明(2 ) 目前使用化學合成藥物,諸如鎭靜劑、抗焦慮劑以及 安眠藥作爲避免及緩和壓力所致之精神與身體症狀。然而 ,此等藥物具有成癮性與副作用問題,故最好勿每日使用 作爲避免壓力所致之精神與身體症狀之目的。因此*具有 此等抗壓迫功效之食品備受需要且發展中,其可重複.並每 曰使用,無安全性之虞,而且其可緩和與避免壓力所致之 金精神與身體症狀。例如,J op an Laid-Open Patent Application 6 - 1 0 0 4 4 2號提出一種含有茶葉中所含 之L -茶胺酸爲有效組份之抗壓迫劑,其可混於加味飮料 (營養補充飮料)中作爲每曰吸收用。此外,亦有報告指 出芳香之壓力舒緩功效(FRAGRANCE JOURNAL: 1 9 9 1 一 1 1 ,4 4 )。不過,尙未有報告指出經乳酸 菌發酵乳具有舒緩及避免壓力所致之精神與身體症狀。 發明掲示 因此,本發明目的係提出可以符合上述社會需要之抗 壓迫劑,其可重覆每日服用無安定性之虞,而且可以緩和 與避免壓力所致之精神與身體症狀。 本發明其它目的係提出具有符合上述社會需要之抗壓 迫功效機能性食品,其可重覆每日作爲食物食用,無安全 性問題。 本發明者徹底硏究發現一種物質,其可以符合上述社 會需要,可用於食品中,並且可以重覆使用無安全之虞。 結果’本發明者注意到經發酵乳具有更佳之抗壓迫功效, 本紙張尺度ilffi巾S國家棵準(CNS)A4規格⑵0 X 297公f ) b - -----r!.-----裝----------訂--------線, (請先Μ讀背面之注項再填寫本頁) 445136 A7 B7 五 '發明說明(3 ) 並完成本發明。 {請先閱讀背面之注意事項再填寫本頁> 根據本發明,提出一種含有經發酵乳作爲有效組份之 抗壓迫劑,以及包含具有抗壓迫功效之坑壓迫劑機能性食 品。 根據本發明,亦提出一種包含經發酵酸乳作爲活性組 份之抗壓迫劑,該經發酵酸乳包括由乳桿菌屬之乳酸菌發 酵動物性乳原材料製備者,以及具有抗壓迫功效之包含抗 壓迫劑機能性食品。 根據本發明,亦提出一種含有經發效酵乳作爲有效組 份之抗壓迫劑,該經發酵酸乳包括以赫耳維希亞乳桿菌乳 酸菌發酵動物性乳原材料製備者,以及具有抗壓迫功效之 包含抗壓迫劑機能性食品。 發明之較佳具體化實例 經濟部智慧財產局員工消費合作社印制取 本發明之抗壓迫劑包含具有抗壓迫功效之經發酵酸乳 作爲有效組合。該抗壓迫劑之抗壓迫功效可以使用血壓上 升、心跳增快以及情緒狀態槪要(ρ 〇 M S )之改變等作 爲指標,藉由測量該藥劑服用前後對於此等上升與改變抑 制功效而確認。 當該包含之經發酵酸乳作爲本發明抗壓迫劑中有效組 份時,使用經乳酸菌發酵乳,慣例上已確認重覆每日使用 該乳相當安全。該經發酵酸乳可以例如’先製備含乳標準 原液製備。 包含於含乳標準原液中之乳可爲動物性或植物性來源 各紙張尺度適用中0國家標準(CNS)A4規格(2】0 X 297公釐) 445136 經濟部智慧財產局員工消費合作社印製 Α7 Β7 五、發明說明(4 ) 。例如可使用。動物性乳,諸如牛乳、小羊乳、綿羊乳或 馬乳:或者來自黃豆等之植物性乳β該乳原材料可爲全月旨 或脫脂乳、乳漿、粉狀乳及/或重組乳。. 該含乳標準原液並不限於乳可溶解或著懸浮且分散於 其中之液體。該標準原液可爲包含諸如糊漿物質之溶·液, 該糊漿係將乳粉或含乳物質與水或鹽類溶液混合製備。此 外,該含乳標準原液中可選擇性含有乳酸菌、酵母萃取物 、維生素、礦物質、糖、脂質、調味劑或著色劑。 之後,以乳酸菌發酵之含乳標準原液,或者以乳酸菌 與酵母共生發酵,以改良該製造機能性食品之口味,如此 製得經發酵酸乳。 該乳酸菌係乳桿菌屬之乳酸菌爲佳。例如,可使用赫 耳維希亞乳桿菌、地耳布魯克乳桿菌之布國亞程、嗜酸乳 桿菌、發酵乳桿菌或乾酪乳桿菌之乾酪亞種。特別是可使 用赫耳維希亞乳桿菌ATC C 5 5 7 9 6、地耳布魯克乳 桿菌布國亞程ATCC 1 1 842、嗜酸乳桿菌ATCC 4356、發酵乳桿菌ATCC1493 1或乾酪乳桿菌 乾酪亞程ATC C 3 9 3之菌株。其中以赫耳維希亞乳桿 囷特佳。 可用以與乳酸菌共生發酵之酵母可爲釀母菌屬、念珠 菌屬或克魯維酵母屬。例如,諸如釀酒酵母、產阮假絲酵 母或馬克斯克魯維酵母之乳酸變種之菌株。 發酵作用之培養條件包括在加熱下使該含乳標準原液 滅菌,冷卻該經減菌標準原液至預定培養溫度,並將包括 本紙張尺度適用t國國家標準(CNS)A4規格(210x297公t ) ' — — — — If In — i I I. · I I I I I I l ll-il — — — — — ^ (請先《讚背面之注意事項再填寫本頁) 445136 A7 B7 五、發明說明(5 ) 事先培養之乳酸菌啓動劑或者事先培養之乳酸菌及酵母啓 (請先Μ讀背面之注項再填寫本頁) 動劑摻入標準原液中。該培養溫度可爲2 0至5 〇°C ’以 3 0至4 5 °C爲佳,而且培養時間可爲3至4 8小時’以 6至2 4小時爲佳。可以乳酸菌數量爲1 08個菌/g或以 上決定終止培養,該乳酸之酸性爲1或以上。用以培養之 乳酸菌啓動劑用量係以乳酸菌對該介質形式表示,以1 〇 5 個菌/g至107個菌/g爲佳。 本發明抗壓迫劑可以包含經發酵酸乳作爲有效組份之 上述經培養溶液本身形式使用,或者以培養溶液形式使用 ,其中經發酵酸乳與乳酸菌以外之組份已被適當分離。在 任一實例中,其中之乳酸菌或者與酵母一起之乳酸菌仍活 著=或者,可以加熱至高達8 0 °C對該經培養溶液或經分 離培養溶液減菌,製備本發明經滅菌型抗壓迫劑。此外, 可純化上述滅菌或非滅菌培養溶液,製得經發酵酸乳:可 以藉由冷凍乾燥、噴霧乾燥,或以桶式乾燥器乾燥粉末化 :或者可以使用媒液或載體進一步製成藥錠。 經濟部智慧財產局員工消費合作社印製 本發明之抗壓迫劑可於任何時候,諸如遭遇壓力前、 遭遇壓力時及遭遇壓力之後使人類或動物口服,而且甚至 可以每日服用。該抗壓迫劑之有效劑量上限並無特殊限制 ’並且可適當地選用。但是當人類服用該抗壓迫劑時,每 天每公斤體重不少於0lg乾燥狀態發酵酸乳爲佳。 本發明具有抗壓迫功效之機能性食品含有上述抗壓迫 劑。因此’其中所含之抗壓迫劑可爲上述培養溶液本身或 適當加工後之形式,其中乳酸菌或者該乳酸菌與酵母仍活
J 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 經濟部智慧財產局員工消費合作社印製 445 136 A7 B7 五、發明說明(6 ) 著;加熱至高達8 0°C滅菌製備之滅菌形式:或者冷凍乾 燥、噴霧乾燥或於桶式乾燥器中乾燥製備之粉狀形式。 只要含有上述抗壓迫劑,本發明之機能性食品並無特 殊限制。該抗壓迫劑可於食品製造後、食品製造期間或食 品製造之任何階段添加。此外,本發明機能性食品可以適 度地包含糖、蛋白質、脂質、維生素.、礦物質、調味料或 著色劑,其視該食品種類而定。本發明機能性食品中所含 之抗壓迫劑並無特殊限制,但是通常爲經發酵酸乳之1 0 至1 0 0 Ow/w%較佳範圍內。 本發明之機能性食品可爲酸酪乳、含乳酸化飲料、乾 酪、含發酵酸乳之加工食品、健康食品或粉化或粒化食品 〇 在人類實例中,本發明機能性食品用於緩和並避免壓 力之有效量以每天每公斤體重不少於0.1g乾燥狀態發 酵酸乳爲佳。 本發明之抗壓迫劑或含有該抗壓迫劑之機能性食品包 含經發酵酸乳作爲有效組份,該酸乳係由乳酸菌發酵製備 。因此,其安全性高,可以每日重覆攝取,並且具有緩和 及避免壓力所致之精神與身體症狀之功效。 實施例 現在參照實施例更詳細解釋本發明,但是本發明不受 限於此。 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) — — — — — — — — — .1 I I. ·ΙΙ — — — — I I-1 I I I f I I J. (請先Μ讀背面之注意事項再填寫本真) 445136 A7 B7 五、發明說明(7 ) 盲施例1 {請先《讀背面之泫意事項再填寫本頁) 將4 0 g事先培養之赫耳維希亞乳桿菌啓動劑與經加 熱至高達9 Ot滅菌之2 k g脫脂乳(固體含量爲9重量 % ),於37 °C培養24小時,製備第二啓動劑。其次將 4 . 5kg脫脂乳粉溶解於45 . 5kg水中,並加·熱至 高達9 0 °C使形成之溶液滅菌,並冷卻至室溫。然後*將 第二啓動劑接種於該溶液,於3 7 °C培養2 4小時製得大 約5 2 k g之發酵酸乳。該發酵酸乳以8 0°C加熱滅菌之 後,將Aspartame (商品名,由Ajinomoto Κ,Κ.所製)摻入 經發酵酸乳中,其用量爲總重之0 . 0 4重量%以促進飮 用,如此製得抗壓迫劑。對於該製得抗壓迫劑進行下列實 驗。 實驗1 以飮料形式將上述抗壓迫劑與包含脂脂乳與相同濃度 乳酸作爲經發酵酸乳之對照組給用於15個健康個體成員 (7男8女,年齡爲24至32),對該成員進行下述心 算試驗。 經濟部智慧財產局員工消費合作社印製 在測量前一天於6 : 00pm及12 : 00pm、測 量當曰7: 00pm以及試驗(10:00am)開始前 3 0分鐘使成員服用用量爲1 0 0個之抗壓迫劑及對照組 ,即其4次總量4 0 0 g。然後,在不同組之日子中以相 同時間表對該成員給用其它抗壓迫劑及對照組。該試驗驗 係以盲目試驗進行,如此劑量順序不會影響試驗結果。爲 本紙張尺度適用中國國家標準(CNS)A4規格(210x297公爱)·川- ' 娜 136 A7 _ B7 五、發明說明(8 ) (請先閱讀背面之注意事項再填寫本頁) 使成員適應試驗環境’試驗開始前該成員進入試驗室10 分鐘’在試驗開始前冷靜至休息狀態β當試驗開始時,成 員保持休息狀態1 5分鐘,然後自試驗開始第1 5分鐘至 第4 5分鐘作3 0分鐘計算工作。試驗時間(自第〇分鐘 至第4 5分鐘)期間’連續測量成員之血壓。此外1 .在試 驗開始之前及計算工作終止之後根據情緒狀態槪要( Ρ 〇 M S )方法評估成員’其可估計隨著時間逝去之心理 狀態,以了解成員之心理狀態。試驗結果顯示如下:血壓 係自休息狀態之血壓改變;而D P M S係由試驗開始之前 各點改變。由成對t 一試驗測定統計差異。 試驗期間(自第0分鐘至第4 5分鐘)舒張血壓波動 示於圖1 。該舒張血壓隨著計算工作之負荷而升高。在成 員給用本發明抗壓迫劑實例中,負擔計算工作壓力期間舒 張血壓之上升被壓抑。特別是在試驗開始後第2 0分鐘時 ,與控制組實例相較,舒張血壓之上升現象明顯地被壓抑 至5 % ( *)明顯水準。 P〇MS試驗結果顯示於圖2。比較試驗開始前與計 算工作後之P OMS結果,給用本發明抗壓迫劑之成員緊 經濟部智慧財產局員工消費合作社印製 張與沮喪容易放鬆,疲勞容易緩和,而情緒紊亂容易被安 定。特別是,與對照組相較,緊張明顯地放鬆5 % ( *)明 顯水準。 實験2 連續7天以上述飮料形式對4個健康個體(3男1女 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 445136 A7 B7 五、發明說明(9 ) ,年齡爲2 5至3 5 )施用該壓迫劑,並於消化該抗壓迫 劑之前與之後進行心算試驗。 <請先Μ讀背面之沒意事項再填莴本頁> 第一天,以同實驗1之相同方式自10 : 30am. 對成員進行心算試驗。隨後,在同日下午給組員服用 1 〇0g該抗壓迫劑。自第2日依序至第6日,組員.上午 及下午給用100g抗壓迫劑。第7天,組員於7 : 00 am·給用l〇〇g抗壓迫劑,自1〇 : 30am.開始 對組員進行同實施例1之心算試驗。試驗結果顯示自其於 試驗狀態下之血壓與心臟速率改變。以成對t -試驗測量 統計差異。 經濟部智慧財產局員工消費合作社印装 試驗期間(自0分鐘至第4 5分鐘)之舒張血壓波動 示於圖3。舒張血壓於負擔計算工作時升高。組員依序服 用本發明抗壓迫劑一週後,與組員服用抗壓迫劑前所進行 之實驗比較,其於負擔計算工作時舒張血壓之上升受到抑 制。此外’試驗期間(自0分鐘至第45分鐘)之心臟速 率波動示於圖4。心臓速率於負擔計算工作時上升。組員 依序服用本發明抗壓迫劑一週後進行之試驗中,與組員服 用抗壓迫劑之前所進行之試驗相較,負擔計算工作期間之 心臟速率上升受到抑制。 實施例2 以8 0 °C加熱1 〇分鐘使實施例1所製備之經發酵酸 乳滅菌。之後’混合原材料製得具有7 5重量%經滅菌發 酵酸乳、13.3重量%之3以1%?1从果膠溶液、
TZ 本紙張尺度適用中國囷家標準(CNS)A4規格(210 X 297公爱) 445136 經濟部智慧財產局員工消费合作社印製 A7 B7 五、發明說明(1〇 ) 3 . 03重量%2 3〇wt%檸檬酸鈉溶液,4 ‘ 5重量 %之1 w t % Aspartame溶液、0.25重量%之經摻和調味劑 與3 . 9 2重量%的水。加熱至高達85 °C使該混合物滅 菌,然後趁熱以每份1 0 0 g裝入棕色瓶中’如此製得經 發酵酸乳飮料。對該製得之經發酵酸乳飮料進行實驗.1之 試驗以揭示其具有對於血壓心臓速率與p 0 M S相似功效 附圖簡述 圖1係顯示實施例1實驗1中心算試驗之試驗期間舒 張血壓的變動圖。該圖縱座標以mmH g表示舒張血壓, 而橫座標以分鐘表示時間。 圖2顯示實施例1實驗1中心算試驗終止後之情緒狀 態槪要(POMS)改變圖。縱座標以POMS分收百分 比表示該改變。 圖3顯示實施例1小組成員給用抗壓迫劑一週時之心 算試驗期間舒張血壓之波動圖。圖之縱座標係以mmH g 表示舒張血壓,橫座標以分鐘表示時間。 圖4係顯示實施例1小組成員給用抗壓迫劑一週時* 於心算試驗之試驗期間心跳速率之波動圖=該圖縱座標以 跳/分表示每分鐘之心跳速率,橫座標以分鐘表示時間。 本紙張尺度適用令國國家標準(CNS)A4規格(210 * 297公釐) lllmn-ll— 裝· — — —訂 i· 線 (請先閱讀背面之注^^項再填寫本頁)
Claims (1)
- C25 3 in 5 4 4 六、申請專利範圍 1 . 一種抗壓迫劑,其包含作爲有效組份之經發酵酸 乳,該經發酵酸乳包括以赫耳維希亞乳桿菌(Lactobacillus helveticus )發酵動物性乳原材料所製備之經發酵酸乳。 2 .如申請專利範圍第1項之抗壓迫劑’其另外包括 選自乳酸菌、酵母、乳酸菌之介質、酵母萃取物、維生素 、礦物質、糖、脂質、調味料、著色劑及其混合物之組份 〇 3 . —種具有抗壓迫功效之機能性食品’其包括如申 請專利範圍第1或2項之抗壓迫劑。 4 .如申請專利範圍第3項之機能性食品’其另外包 括選自糖、蛋白質、脂質、維生素、礦物質、調味料、著 色劑及其混合物之組份。 5 .如申請專利範圍第3項之機能性食品,其中該機 能性食品中抗壓迫劑之含量係以1 〇至1 〇 〇 w/w %之 經發酵酸乳表示。 6 .如申請專利範圍第3項之機能性食品,其中該機 能性食品係選自酸酪乳、含乳酸化飮料、乾酪、含發酵酸 乳之加工製品、粉狀食品及粒狀食品。 ------r--« — — III ------------------ <請先閱讀背面之沒意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -14-
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP20850496A JP4065038B2 (ja) | 1996-08-07 | 1996-08-07 | 計算作業負荷ストレス緩和剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW445136B true TW445136B (en) | 2001-07-11 |
Family
ID=16557259
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW086111250A TW445136B (en) | 1996-08-07 | 1997-08-06 | Anti-stress agent and functional food having anti-stress effect |
Country Status (23)
Country | Link |
---|---|
US (1) | US6596301B1 (zh) |
EP (1) | EP0966969B1 (zh) |
JP (1) | JP4065038B2 (zh) |
KR (1) | KR100331141B1 (zh) |
CN (1) | CN1112931C (zh) |
AR (1) | AR009005A1 (zh) |
AT (1) | ATE294586T1 (zh) |
AU (1) | AU719204B2 (zh) |
BG (1) | BG63074B1 (zh) |
BR (1) | BR9711126A (zh) |
CA (1) | CA2262652C (zh) |
CZ (1) | CZ299912B6 (zh) |
DE (1) | DE69733215T2 (zh) |
ES (1) | ES2239784T3 (zh) |
ID (1) | ID19984A (zh) |
MX (1) | MXPA99001203A (zh) |
MY (1) | MY124559A (zh) |
PT (1) | PT966969E (zh) |
SK (1) | SK285323B6 (zh) |
TR (1) | TR199900233T2 (zh) |
TW (1) | TW445136B (zh) |
WO (1) | WO1998005343A1 (zh) |
ZA (1) | ZA976989B (zh) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4727770B2 (ja) * | 1997-09-26 | 2011-07-20 | カルピス株式会社 | 尿中カテコールアミン低下、尿中ノルアドレナリン低下、尿中ドーパミン低下及びFischer比低下の少なくとも1つの軽減剤 |
FR2793257B1 (fr) | 1999-05-06 | 2001-07-27 | Gervais Danone Sa | Bacteries lactiques a proprietes anxiolytiques, et leurs utilisations |
SE523771C2 (sv) * | 1999-05-21 | 2004-05-18 | Probi Ab | Sportdryck innehållande mikronäringsämnen i kombination med levande laktobaciller |
GB0027761D0 (en) | 2000-11-14 | 2000-12-27 | Nestle Sa | Nutritional composition for an immune condition |
US7718171B2 (en) | 2003-04-07 | 2010-05-18 | Chr. Hansen A/S | Reducing heart rate in mammals using milk derived fermentation products produced using Lactobacillus helveticus |
EP1466529A1 (en) * | 2003-04-07 | 2004-10-13 | Chr. Hansen A/S | Composition with heart rate reducing properties |
US20040265279A1 (en) * | 2003-05-08 | 2004-12-30 | Timothy Dinan | Probiotics in the treatment of atypical depression and other disorders characterized by hypothalamic pitiuitary-adrenal axis over-activity |
JP4680571B2 (ja) * | 2003-12-25 | 2011-05-11 | カルピス株式会社 | 経口摂取用保湿剤 |
ATE532416T1 (de) * | 2004-09-03 | 2011-11-15 | Chr Hansen As | Fermentierte milchproteine mit rezeptor-ligand und ihre verwendungen |
US8097246B2 (en) | 2005-06-24 | 2012-01-17 | Calpis Co., Ltd. | Promoter of differentiation and keratinization of epidermic cell and functional beverage/food for promotion of keratinization of epidermis |
JP2007031309A (ja) * | 2005-07-25 | 2007-02-08 | Tokiwa Yakuhin Kogyo Kk | 抗ストレス組成物 |
US20090299036A1 (en) | 2006-02-14 | 2009-12-03 | Calpis Co, Ltd | Agent for preventing arteriosclerosis, agent for suppressing vascular intimal thickening and agent for improving vascular endothelial function |
CN101678051B (zh) * | 2006-09-04 | 2012-12-12 | 雪印惠乳业株式会社 | 促进血中脂连蛋白浓度增加及/或抑制其减少的制剂及内脏脂肪蓄积抑制剂 |
JP2009046456A (ja) * | 2007-08-23 | 2009-03-05 | Kikkoman Corp | 生殖行動の誘発用組成物 |
JP2008214253A (ja) | 2007-03-02 | 2008-09-18 | Snow Brand Milk Prod Co Ltd | 内臓脂肪減少剤 |
SG182959A1 (en) * | 2007-03-30 | 2012-08-30 | Suntory Holdings Ltd | Medicinal composition, food or drink having effect of enhancing parasympathetic nervous activity |
US20090022853A1 (en) * | 2007-07-16 | 2009-01-22 | Conopco, Inc., D/B/A Unilever | Beverage |
WO2010026136A1 (en) * | 2008-09-05 | 2010-03-11 | Unilever Nv | Beverages comprising potassium |
US8273380B1 (en) | 2009-05-19 | 2012-09-25 | Jetway Inc. | Fortified beverage for minimizing and/or preventing jet lag |
US8928336B2 (en) | 2011-06-09 | 2015-01-06 | Ford Global Technologies, Llc | Proximity switch having sensitivity control and method therefor |
US8975903B2 (en) | 2011-06-09 | 2015-03-10 | Ford Global Technologies, Llc | Proximity switch having learned sensitivity and method therefor |
US10004286B2 (en) | 2011-08-08 | 2018-06-26 | Ford Global Technologies, Llc | Glove having conductive ink and method of interacting with proximity sensor |
US8994228B2 (en) | 2011-11-03 | 2015-03-31 | Ford Global Technologies, Llc | Proximity switch having wrong touch feedback |
US10112556B2 (en) | 2011-11-03 | 2018-10-30 | Ford Global Technologies, Llc | Proximity switch having wrong touch adaptive learning and method |
US9520875B2 (en) | 2012-04-11 | 2016-12-13 | Ford Global Technologies, Llc | Pliable proximity switch assembly and activation method |
US9568527B2 (en) | 2012-04-11 | 2017-02-14 | Ford Global Technologies, Llc | Proximity switch assembly and activation method having virtual button mode |
US9287864B2 (en) | 2012-04-11 | 2016-03-15 | Ford Global Technologies, Llc | Proximity switch assembly and calibration method therefor |
US9660644B2 (en) | 2012-04-11 | 2017-05-23 | Ford Global Technologies, Llc | Proximity switch assembly and activation method |
US8933708B2 (en) | 2012-04-11 | 2015-01-13 | Ford Global Technologies, Llc | Proximity switch assembly and activation method with exploration mode |
US9559688B2 (en) | 2012-04-11 | 2017-01-31 | Ford Global Technologies, Llc | Proximity switch assembly having pliable surface and depression |
US9197206B2 (en) | 2012-04-11 | 2015-11-24 | Ford Global Technologies, Llc | Proximity switch having differential contact surface |
US9065447B2 (en) | 2012-04-11 | 2015-06-23 | Ford Global Technologies, Llc | Proximity switch assembly and method having adaptive time delay |
US9184745B2 (en) | 2012-04-11 | 2015-11-10 | Ford Global Technologies, Llc | Proximity switch assembly and method of sensing user input based on signal rate of change |
US9831870B2 (en) | 2012-04-11 | 2017-11-28 | Ford Global Technologies, Llc | Proximity switch assembly and method of tuning same |
US9219472B2 (en) | 2012-04-11 | 2015-12-22 | Ford Global Technologies, Llc | Proximity switch assembly and activation method using rate monitoring |
US9944237B2 (en) | 2012-04-11 | 2018-04-17 | Ford Global Technologies, Llc | Proximity switch assembly with signal drift rejection and method |
US9531379B2 (en) | 2012-04-11 | 2016-12-27 | Ford Global Technologies, Llc | Proximity switch assembly having groove between adjacent proximity sensors |
US9136840B2 (en) | 2012-05-17 | 2015-09-15 | Ford Global Technologies, Llc | Proximity switch assembly having dynamic tuned threshold |
US8981602B2 (en) | 2012-05-29 | 2015-03-17 | Ford Global Technologies, Llc | Proximity switch assembly having non-switch contact and method |
US9337832B2 (en) | 2012-06-06 | 2016-05-10 | Ford Global Technologies, Llc | Proximity switch and method of adjusting sensitivity therefor |
US9641172B2 (en) | 2012-06-27 | 2017-05-02 | Ford Global Technologies, Llc | Proximity switch assembly having varying size electrode fingers |
US8922340B2 (en) | 2012-09-11 | 2014-12-30 | Ford Global Technologies, Llc | Proximity switch based door latch release |
US8796575B2 (en) | 2012-10-31 | 2014-08-05 | Ford Global Technologies, Llc | Proximity switch assembly having ground layer |
US9311204B2 (en) | 2013-03-13 | 2016-04-12 | Ford Global Technologies, Llc | Proximity interface development system having replicator and method |
WO2015133122A1 (ja) * | 2014-03-04 | 2015-09-11 | カルピス株式会社 | 鎮静用の自律神経調整剤及び日周リズム改善剤 |
US10038443B2 (en) | 2014-10-20 | 2018-07-31 | Ford Global Technologies, Llc | Directional proximity switch assembly |
US9654103B2 (en) | 2015-03-18 | 2017-05-16 | Ford Global Technologies, Llc | Proximity switch assembly having haptic feedback and method |
US9548733B2 (en) | 2015-05-20 | 2017-01-17 | Ford Global Technologies, Llc | Proximity sensor assembly having interleaved electrode configuration |
JP6285994B2 (ja) * | 2016-08-09 | 2018-02-28 | 株式会社明治 | シトルリン含有発酵乳およびその製造方法 |
KR20180019474A (ko) * | 2016-08-16 | 2018-02-26 | 주식회사 엠디헬스케어 | 락토바실러스 플란타룸 유래 소포를 포함하는 정신질환 예방 또는 치료용 조성물 |
JP2018075036A (ja) * | 2018-02-02 | 2018-05-17 | 株式会社明治 | シトルリン含有発酵乳およびその製造方法 |
WO2019188868A1 (ja) * | 2018-03-27 | 2019-10-03 | 森永乳業株式会社 | 抗ストレス用組成物 |
JP2020039308A (ja) * | 2018-09-12 | 2020-03-19 | キリンホールディングス株式会社 | 労働パフォーマンスの向上用組成物 |
WO2022196488A1 (ja) * | 2021-03-15 | 2022-09-22 | 森永乳業株式会社 | Qolを改善するための組成物 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6153216A (ja) * | 1984-08-23 | 1986-03-17 | Rikagaku Kenkyusho | 高血圧症予防治療剤 |
JPS61153216A (ja) | 1984-12-27 | 1986-07-11 | Kawasaki Steel Corp | 高炉内への粉体吹き込み方法 |
US4931430A (en) * | 1987-12-14 | 1990-06-05 | E. R. Squibb & Sons, Inc. | Method for preventing or treating anxiety employing an ACE inhibitor |
JP2855283B2 (ja) * | 1990-04-23 | 1999-02-10 | 株式会社ヤクルト本社 | 抗潰瘍剤およびその製造法 |
CH683223A5 (fr) | 1991-10-25 | 1994-02-15 | Nestle Sa | Procédé de préparation d'un lait acidifié. |
JP2782142B2 (ja) * | 1992-07-23 | 1998-07-30 | カルピス株式会社 | アンジオテンシン変換酵素阻害剤及びその製造法 |
FR2703219B1 (fr) * | 1993-04-01 | 1995-05-05 | Abram Cala | Le pain fait au kéfir. |
KR960009004B1 (ko) * | 1993-09-01 | 1996-07-10 | 안기영 | 셀레늄 함유 유산균 식품 및 그의 제조방법 |
JP2824821B2 (ja) * | 1993-11-04 | 1998-11-18 | カルピス株式会社 | 乳酸菌及び発酵乳製品 |
DE4411108A1 (de) * | 1994-03-30 | 1995-10-05 | Basf Ag | Verwendung von fermentativ erhaltenen Milchprodukten zur Behandlung von Hauterkrankungen |
JP2855078B2 (ja) * | 1994-08-16 | 1999-02-10 | 雪印乳業株式会社 | ケフィール様発酵乳とその製造方法 |
-
1996
- 1996-08-07 JP JP20850496A patent/JP4065038B2/ja not_active Expired - Lifetime
-
1997
- 1997-08-06 AR ARP970103564A patent/AR009005A1/es not_active Application Discontinuation
- 1997-08-06 DE DE69733215T patent/DE69733215T2/de not_active Expired - Lifetime
- 1997-08-06 BR BR9711126-0A patent/BR9711126A/pt not_active Application Discontinuation
- 1997-08-06 KR KR1019997001032A patent/KR100331141B1/ko not_active IP Right Cessation
- 1997-08-06 PT PT97934703T patent/PT966969E/pt unknown
- 1997-08-06 CN CN97198594A patent/CN1112931C/zh not_active Expired - Fee Related
- 1997-08-06 CZ CZ0038699A patent/CZ299912B6/cs not_active IP Right Cessation
- 1997-08-06 ES ES97934703T patent/ES2239784T3/es not_active Expired - Lifetime
- 1997-08-06 CA CA002262652A patent/CA2262652C/en not_active Expired - Fee Related
- 1997-08-06 WO PCT/JP1997/002728 patent/WO1998005343A1/ja active IP Right Grant
- 1997-08-06 TW TW086111250A patent/TW445136B/zh not_active IP Right Cessation
- 1997-08-06 MX MXPA99001203A patent/MXPA99001203A/es not_active IP Right Cessation
- 1997-08-06 ZA ZA976989A patent/ZA976989B/xx unknown
- 1997-08-06 AU AU37828/97A patent/AU719204B2/en not_active Ceased
- 1997-08-06 EP EP97934703A patent/EP0966969B1/en not_active Expired - Lifetime
- 1997-08-06 AT AT97934703T patent/ATE294586T1/de active
- 1997-08-06 US US09/242,239 patent/US6596301B1/en not_active Expired - Fee Related
- 1997-08-06 TR TR1999/00233T patent/TR199900233T2/xx unknown
- 1997-08-06 SK SK145-99A patent/SK285323B6/sk not_active IP Right Cessation
- 1997-08-06 MY MYPI97003590A patent/MY124559A/en unknown
- 1997-08-07 ID IDP972738A patent/ID19984A/id unknown
-
1999
- 1999-03-05 BG BG103228A patent/BG63074B1/bg unknown
Also Published As
Publication number | Publication date |
---|---|
BR9711126A (pt) | 2000-01-11 |
DE69733215T2 (de) | 2006-02-16 |
CZ299912B6 (cs) | 2008-12-29 |
PT966969E (pt) | 2005-08-31 |
EP0966969A1 (en) | 1999-12-29 |
AR009005A1 (es) | 2000-03-08 |
EP0966969A4 (en) | 2000-04-26 |
US6596301B1 (en) | 2003-07-22 |
CN1112931C (zh) | 2003-07-02 |
CZ38699A3 (cs) | 1999-07-14 |
AU3782897A (en) | 1998-02-25 |
ATE294586T1 (de) | 2005-05-15 |
TR199900233T2 (xx) | 1999-06-21 |
JPH1045610A (ja) | 1998-02-17 |
KR20000029867A (ko) | 2000-05-25 |
ID19984A (id) | 1998-09-03 |
CN1232400A (zh) | 1999-10-20 |
ES2239784T3 (es) | 2005-10-01 |
EP0966969B1 (en) | 2005-05-04 |
BG103228A (en) | 2000-05-31 |
SK285323B6 (sk) | 2006-11-03 |
CA2262652A1 (en) | 1998-02-12 |
ZA976989B (en) | 1999-05-06 |
CA2262652C (en) | 2004-02-10 |
AU719204B2 (en) | 2000-05-04 |
JP4065038B2 (ja) | 2008-03-19 |
BG63074B1 (bg) | 2001-03-30 |
KR100331141B1 (ko) | 2002-04-01 |
SK14599A3 (en) | 2000-03-13 |
WO1998005343A1 (fr) | 1998-02-12 |
MXPA99001203A (es) | 2004-11-22 |
MY124559A (en) | 2006-06-30 |
DE69733215D1 (de) | 2005-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW445136B (en) | Anti-stress agent and functional food having anti-stress effect | |
Nagpal et al. | Milk, milk products, and disease free health: an updated overview | |
EP3442549B1 (en) | Bifidobacteria for increasing lean body mass | |
TW200533299A (en) | Functional food for improving endogenous rhythm of melatonin secretion, and functional food for improving circadian rhythm | |
JPWO2019188806A1 (ja) | 睡眠促進用組成物並びに該睡眠促進用組成物を用いた医薬品組成物及び飲食品組成物 | |
US8921310B2 (en) | Method for accelerating mammalian body fat metabolism | |
JP2019513390A (ja) | 食物、エネルギーおよび/または脂肪の摂取を減少させるためのビフィズス菌(Bifidobacterium) | |
JP7433220B2 (ja) | 月経随伴症状の処置のための組成物 | |
JP6037595B2 (ja) | 満腹感誘導組成物及びその製造方法 | |
JP2006273745A (ja) | 免疫賦活・アレルギー改善材およびその製造方法、ならびに免疫賦活・アレルギー改善作用を有する食品組成物および医薬組成物 | |
TWI530256B (zh) | 以鐵結合型乳鐵蛋白製備抗精神疲勞劑之方法 | |
WO2018123873A1 (ja) | 発汗促進用組成物 | |
JP3715640B1 (ja) | ストレス由来の皮膚血流低下改善用組成物、皮膚機能改善用組成物およびそれらを用いた飲食品 | |
JP4435882B2 (ja) | アルコール吸収抑制組成物 | |
JP2010037225A (ja) | 乳清ケフィアを有効成分として含んでなる体脂肪減少剤 | |
천정환 et al. | Nutritional functions of milk and dairy products in improving human health | |
PL190433B1 (pl) | Zastosowanie fermentowanego kwaśnego mleka do wyttaaarzania środka lub produktu żywnościowego zapobiegającego lub łagodzącego objawy stresu | |
Yıldız | 1 Overview of Yogurt and Other Fermented Dairy Products | |
US20170105445A1 (en) | Enteral formulations for preterm infants comprising optimised phenylalanine intake levels |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GD4A | Issue of patent certificate for granted invention patent | ||
MM4A | Annulment or lapse of patent due to non-payment of fees |